Acura Pharmaceuticals, Inc. ACUR
OTC PK
| 09/30/2021 | 06/30/2021 | 03/31/2021 | 12/31/2020 | 09/30/2020 | |
|---|---|---|---|---|---|
| Revenue | 2.25M | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.25M | -- | -- | -- | -- |
| Cost of Revenue | 1.61M | -- | -- | -- | -- |
| Gross Profit | 635.00K | -- | -- | -- | -- |
| SG&A Expenses | 1.74M | -- | -- | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.35M | -- | -- | -- | -- |
| Operating Income | -1.11M | -- | -- | -- | -- |
| Income Before Tax | -1.15M | -- | -- | -- | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.15 | -- | -- | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.15M | -- | -- | -- | -- |
| EBIT | -1.11M | -- | -- | -- | -- |
| EBITDA | -1.03M | -- | -- | -- | -- |
| EPS Basic | -0.03 | -- | -- | -- | -- |
| Normalized Basic EPS | -0.02 | -- | -- | -- | -- |
| EPS Diluted | -0.03 | -- | -- | -- | -- |
| Normalized Diluted EPS | -0.02 | -- | -- | -- | -- |
| Average Basic Shares Outstanding | 183.28M | -- | -- | -- | -- |
| Average Diluted Shares Outstanding | 183.28M | -- | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |